Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Racepinephrine is a bronchodilator used to treat intermittent asthma. Racepinephrine is a racemic mixture consisting of d-DB00668 and l-DB00668 enantiomers.
- Mechanism
- Curator reviewed · 2 references
Epinephrine is a non-selective agonist at α- and β-adrenergic receptors, which are all G-protein-coupled receptors. The main therapeutic effect of epinephrine arises from its agonist action on β2-adrenergic receptors, which activate adenylyl cyclase and increase intracellular cyclic AMP production. Epinephrine causes smooth muscle relaxation on various tissues, including bronchial smooth muscles. As a result, epinephrine serves to alleviate bronchospasm, wheezing and tightness of chest that may occur during asthmatic attacks. Via its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder, epinephrine may also alleviate pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis.
Epinephrine also acts on the α-adrenergic receptors on vascular smooth muscles, particularly in the skin and splanchnic vascular beds, to cause constriction. Epinephrine is thought to reduce capillary leakage by constricting precapillary arterioles, reducing hydrostatic pressure and consequently bronchial mucosal edema.
- Primary indication
- Indicated for temporary relief of mild symptoms of intermittent asthma.Curator reviewed · 1 structured indication
- First approval
- Canada, 1999
- Brand names
- Asthmanefrin
- S-2
Resolves to
What you can answer from here — as of October 01, 2026
Which drugs share a target with Racepinephrine, and which of those have an active Phase 3 trial?